Skip to main content
HR 3282 118th Congress House Health Government information and archives Health care costs and insurance Health information and medical records Medicare Prescription drugs

Promoting Transparency and Healthy Competition in Medicare Act

Introduced: May 15, 2023 Introduced by: Harshbarger, Diana Republican · Tennessee See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
May 19, 2023
Referred to the Subcommittee on Health.
May 15, 2023
Introduced in House
May 15, 2023
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Promoting Transparency and Healthy Competition in Medicare Act

This bill requires Medicare Advantage (MA) organizations and prescription drug plan (PDP) sponsors and pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit to report certain information relating to their ownership interests in participating providers.

Specifically, MA organizations must report on items and services, patient risk scores and associated diagnoses, prior authorization requests, and incentive payments with respect to providers in which the MA organization has an ownership interest as compared to other providers.

Similarly, PDP sponsors under the Medicare prescription drug benefit must report on the prices of prescription drugs with respect to pharmacies in which the PDP sponsor has an ownership interest as compared to other pharmacies. The bill also prohibits PDP sponsors from contracting with PBMs in which the PDP sponsor has an ownership interest unless the PBM reports certain information on rebates and payments between the PBM, PDP sponsor, pharmacies, and drug manufacturers.

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • HR 3561 Related bill PATIENT Act of 2023
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 3
All 3 Democratic 2 Republican 1
R
Bilirakis, Gus M.
Florida · May 15, 2023
 D
Schakowsky, Janice D.
Illinois · May 15, 2023
 D
Schrier, Kim
Washington · May 15, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3282: Promoting Transparency and Healthy Competition in Medicare Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-3282/
MLA
"H.R. 3282: Promoting Transparency and Healthy Competition in Medicare Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-3282/.
Bluebook (legal)
H.R. 3282, 118th Cong. (2026), https://openamerica.io/bill/118-HR-3282/.
Markdown link
[H.R. 3282: Promoting Transparency and Healthy Competition in Medicare Act](https://openamerica.io/bill/118-HR-3282/)
Report a problem